|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wu SJ, Huang SY, Lin CT, Lin YJ, Chang CJ
and Tien HF: The incidence of chronic lymphocytic leukemia in
Taiwan, 1986-2005: A distinct increasing trend with birth-cohort
effect. Blood. 116:4430–4435. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ko BS, Chen LJ, Huang HH, Chen HM and
Hsiao FY: Epidemiology, treatment patterns and survival of chronic
lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in
Taiwan, 2006-2015. Int J Clin Pract. 75(e14258)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Raufi A, Alsharedi M, Khelfa Y, Griswold
DC and Lebowicz Y: Leukemia cutis in a patient with chronic
lymphocytic leukemia presenting as bilateral helical nodules. SAGE
Open Med Case Rep. 4(2050313X16683624)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hallek M, Cheson BD, Catovsky D,
Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M,
Montserrat E, Chiorazzi N, et al: iwCLL guidelines for diagnosis,
indications for treatment, response assessment, and supportive
management of CLL. Blood. 131:2745–2760. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Van Dyke DL, Werner L, Rassenti LZ,
Neuberg D, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M,
Sreekantaiah C, Greaves AW, et al: The Dohner fluorescence in situ
hybridization prognostic classification of chronic lymphocytic
leukaemia (CLL): The CLL Research Consortium experience. Br J
Haematol. 173:105–113. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Michallet AS, Aktan M, Hiddemann W, Ilhan
O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, et
al: Rituximab plus bendamustine or chlorambucil for chronic
lymphocytic leukemia: Primary analysis of the randomized,
open-label MABLE study. Haematologica. 103:698–706. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Preetesh J, Michael JK, William GW,
Mariela S, Philip AT, Alessandra F, Zeev E, Hagop K, Susan O and
Jan AB: Long-term follow-up of treatment with ibrutinib and
rituximab in patients with high-risk chronic lymphocytic leukemia.
Clin Cancer Res. 23:2154–2158. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Meignan M, Gallamini A and Haioun C:
Report on the first international workshop on interim-pet-scan in
lymphoma. Leuk Lymphoma. 50:1257–1260. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wagner G, Fenchel K, Back W, Schulz A and
Sachse MM: Leukemia cutis-epidemiology, clinical presentation, and
differential diagnoses. J Dtsch Dermatol Ge. 10:27–36.
2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lazarian G, Munger M, Quinquenel A,
Dilhuydy MS, Veronese L, Luque Paz D, Guièze R, Ledoux-Pilon A,
Paillassa J, Merabet F, et al: Clinical and biological
characteristics of leukemia cutis in chronic lymphocytic leukemia:
A study of the French innovative leukemia organization (FILO). Am J
Hematol. 96:E353–E356. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Velez NF, Karia PS, Vartanov AR, Davids
MS, Brown JR and Schmults CD: Association of advanced leukemic
stage and skin cancer tumor stage with poor skin cancer outcomes in
patients with chronic lymphocytic leukemia. JAMA Dermatol.
150:280–287. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gao S, Shu H and Yang H: Imaging features
of skeletal muscle lymphoma: A case report and literature review.
BMC Med Imaging. 21(136)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mollejo M and Piris MA: The complex
pathology and differential diagnosis of splenic and nodal marginal
zone lymphoma. Ann Lymphoma. 4:1–14. 2020.
|
|
15
|
Julie M Vose: Mantle cell lymphoma: 2017
update on diagnosis, risk-stratification, and clinical management.
Am J Hematol. 92:806–813. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E and Lister TA: Alliance,
Australasian Leukaemia, Lymphoma Group, Eastern Cooperative
Oncology Group et al. Recommendations for initial
evaluation, staging, and response assessment of hodgkin and
non-hodgkin lymphoma: The lugano classification. J Clin Oncol.
32:3059–3068. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
National Comprehensive Cancer Network:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (version
1.2024). https://www.nccn.org/professionals/physician_gls/pdf/cll_blocks.pdf.
|
|
18
|
Maeshima AM, Taniguchi H, Fujino T, Saito
Y, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, et al:
Immunohistochemical CD20-negative change in B-cell non-Hodgkin
lymphomas after rituximab-containing therapy. Ann Hematol.
99:2141–2148. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hiraga J, Tomita A, Sugimoto T, Shimada K,
Ito M, Nakamura S, Kiyoi H, Kinoshita T and Naoe T: Down-regulation
of CD20 expression in B-cell lymphoma cells after treatment with
rituximab-containing combination chemotherapies: Its prevalence and
clinical significance. Blood. 113:4885–4893. 2009.PubMed/NCBI View Article : Google Scholar
|
